Vivani Medical Appoints New CFO, Directors
Ticker: VANI · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1266806
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-composition
TL;DR
Vivani Medical shakes up leadership with new CFO and directors, expect strategic shifts.
AI Summary
Vivani Medical, Inc. announced on March 4, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David R. Chen and Mr. David L. Johnson, and appointed Mr. Michael L. Ringer as Chief Financial Officer. The filing also details compensatory arrangements for these officers.
Why It Matters
Changes in key leadership and executive compensation can signal shifts in company strategy and financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Vivani Medical, Inc. (company) — Registrant
- Dr. David R. Chen (person) — Newly elected director
- Mr. David L. Johnson (person) — Newly elected director
- Mr. Michael L. Ringer (person) — Appointed Chief Financial Officer
- March 4, 2024 (date) — Date of earliest event reported
FAQ
Who were the newly elected directors at Vivani Medical, Inc.?
Dr. David R. Chen and Mr. David L. Johnson were elected as new directors.
Who has been appointed as the new Chief Financial Officer?
Mr. Michael L. Ringer has been appointed as the Chief Financial Officer.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 4, 2024.
What is Vivani Medical, Inc.'s principal executive office address?
Vivani Medical, Inc.'s principal executive office is located at 1350 S. Loop Road, Alameda, California, 94502.
What are the main items disclosed in this 8-K filing?
This 8-K filing discloses the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-03-06 08:30:34
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share VANI The Nasdaq Capital
- $35,000 — led to receive annual cash retainers of $35,000 for serving as a member of the Board an
- $10,000 — or serving as a member of the Board and $10,000 for serving as a member of the Audit Co
Filing Documents
- g084105_8k.htm (8-K) — 35KB
- g084105_ex99-1.htm (EX-99.1) — 15KB
- 0001753926-24-000474.txt ( ) — 223KB
- vani-20240304.xsd (EX-101.SCH) — 3KB
- vani-20240304_lab.xml (EX-101.LAB) — 33KB
- vani-20240304_pre.xml (EX-101.PRE) — 22KB
- g084105_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIVANI MEDICAL, INC. Date: March 6, 2024 By: /s/ Brigid Makes Brigid Makes Chief Financial Officer (Principal Financial and Accounting Officer)